Literature DB >> 6415029

Immunoactive peptides, FK-156 and FK-565. I. Enhancement of host resistance to microbial infection in mice.

Y Mine, Y Yokota, Y Wakai, S Fukada, M Nishida, S Goto, S Kuwahara.   

Abstract

The protective effect of an immunoactive peptide, D-lactoyl-L-alanyl-gamma-D-glutamyl-(L)-meso-diaminopimelyl-(L)-glycine (FK-156) and a related compound, heptanoyl-gamma-D-glutamyl-(L)-meso-diaminopimelyl-(D)-alanine (FK-565) was determined in mice with various kinds of microbial infections. FK-156 and FK-565 were given to mice either subcutaneously or orally before challenge. The drugs enhanced significantly the defense of mice against acute systemic infections induced by various extracellular and facultative intracellular organisms, and subcutaneous abscess by Staphylococcus aureus. The protective effect of these drugs against Escherichia coli infection differed considerably depending on the route of administration; FK-156 was only effective by the parenteral route; however, FK-565 was effective by both parenteral and oral routes. After subcutaneous dosing with FK-156, the enhancement of host defense of mice against E. coli infection was more rapid than against Listeria infection. The enhancing effects of FK-156 and FK-565 on host defense of mice against pseudomonal infection was more potent than other immunoactive drugs.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6415029     DOI: 10.7164/antibiotics.36.1045

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN: 0021-8820            Impact factor:   2.649


  14 in total

Review 1.  Modulating immunity as a therapy for bacterial infections.

Authors:  Robert E W Hancock; Anastasia Nijnik; Dana J Philpott
Journal:  Nat Rev Microbiol       Date:  2012-03-16       Impact factor: 60.633

Review 2.  Immunomodulators isolated from microorganisms.

Authors:  Z Vanĕk; J Matĕjů; E Curdová
Journal:  Folia Microbiol (Praha)       Date:  1991       Impact factor: 2.099

Review 3.  Unleashing the therapeutic potential of NOD-like receptors.

Authors:  Kaoru Geddes; João G Magalhães; Stephen E Girardin
Journal:  Nat Rev Drug Discov       Date:  2009-06       Impact factor: 84.694

Review 4.  Immunomodulating peptides.

Authors:  G H Werner; F Floc'h; D Migliore-Samour; P Jollès
Journal:  Experientia       Date:  1986-05-15

5.  Structure-activity relationships in nucleotide oligomerization domain 1 (Nod1) agonistic γ-glutamyldiaminopimelic acid derivatives.

Authors:  Geetanjali Agnihotri; Rehman Ukani; Subbalakshmi S Malladi; Hemamali J Warshakoon; Rajalakshmi Balakrishna; Xinkun Wang; Sunil A David
Journal:  J Med Chem       Date:  2011-02-07       Impact factor: 7.446

6.  A Comprehensive Study of the Interaction between Peptidoglycan Fragments and the Extracellular Domain of Mycobacterium tuberculosis Ser/Thr Kinase PknB.

Authors:  Qianqian Wang; Roberta Marchetti; Sladjana Prisic; Kentaro Ishii; Yohei Arai; Ippei Ohta; Shinsuke Inuki; Susumu Uchiyama; Alba Silipo; Antonio Molinaro; Robert N Husson; Koichi Fukase; Yukari Fujimoto
Journal:  Chembiochem       Date:  2017-09-14       Impact factor: 3.164

7.  Synergism of synthetic acyltripeptide and its analogs with recombinant interferon gamma for activation of antitumor properties of human blood monocytes.

Authors:  S Sone; A Okubo; N Inamura; A Nii; T Ogura
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

8.  Activation by a new synthetic acyltripeptide and its analogs entrapped in liposomes of rat alveolar macrophages to the tumor cytotoxic state.

Authors:  S Sone; S Mutsuura; M Ogawara; T Utsugi; E Tsubura
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

9.  Tumor cytotoxicity of human monocyte membrane-bound interleukin-1 alpha induced by synergistic actions of interferon-gamma and synthetic acyltripeptide, FK-565.

Authors:  N Inamura; S Sone; A Okubo; E Kunishige; M Nakanishi; T Ogura
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

10.  Effect of anticancer drugs on the release of tumour necrosis factor in vitro.

Authors:  S I Hasan; K Ahmed; J L Turk
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.